[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 130, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 1366917, "exercisedValue": 41362, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 50, "title": "Executive VP & CFO", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 805042, "exercisedValue": 586039, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 66, "title": "Executive Vice President of Clinical Development", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 896847, "exercisedValue": 7759965, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arturo M. Molina FACP, M.D., M.S.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 956912, "exercisedValue": 1160875, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & CTO", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Newman  Yeilding", "title": "Executive VP, Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling J.D.", "age": 53, "title": "Executive VP and Chief Legal & Business Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Senior VP & Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 60, "title": "EVP & Chief Discovery Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 53, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 64.98, "open": 64.59, "dayLow": 64.56, "dayHigh": 65.38, "regularMarketPreviousClose": 64.98, "regularMarketOpen": 64.59, "regularMarketDayLow": 64.56, "regularMarketDayHigh": 65.38, "payoutRatio": 0.0, "beta": 2.202, "trailingPE": 88.80822, "forwardPE": -45.335667, "volume": 612543, "regularMarketVolume": 612543, "averageVolume": 839170, "averageVolume10days": 1007060, "averageDailyVolume10Day": 1007060, "bid": 46.56, "ask": 83.02, "bidSize": 2, "askSize": 2, "marketCap": 4033159936, "fiftyTwoWeekLow": 33.31, "fiftyTwoWeekHigh": 68.26, "allTimeHigh": 68.26, "allTimeLow": 4.47, "priceToSalesTrailing12Months": 19.280811, "fiftyDayAverage": 58.4917, "twoHundredDayAverage": 48.794773, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3473973760, "profitMargins": 0.24877001, "floatShares": 43163457, "sharesOutstanding": 62211318, "sharesShort": 6659476, "sharesShortPriorMonth": 6310889, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.107, "heldPercentInsiders": 0.01018, "heldPercentInstitutions": 1.1632199, "shortRatio": 7.36, "shortPercentOfFloat": 0.1283, "impliedSharesOutstanding": 62211318, "bookValue": 10.756, "priceToBook": 6.027334, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": 52038000, "trailingEps": 0.73, "forwardEps": -1.43, "enterpriseToRevenue": 16.608, "enterpriseToEbitda": 139.697, "52WeekChange": 0.480137, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 64.83, "targetHighPrice": 82.0, "targetLowPrice": 47.0, "targetMeanPrice": 70.30769, "targetMedianPrice": 72.0, "recommendationMean": 1.46154, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 570465024, "totalCashPerShare": 9.17, "ebitda": 24868000, "totalDebt": 11279000, "quickRatio": 16.854, "currentRatio": 16.969, "totalRevenue": 209180000, "debtToEquity": 1.688, "revenuePerShare": 3.339, "returnOnAssets": 0.02249, "returnOnEquity": 0.08606, "grossProfits": 209180000, "freeCashflow": 26000000, "operatingCashflow": 39542000, "revenueGrowth": 0.331, "grossMargins": 1.0, "ebitdaMargins": 0.118879996, "operatingMargins": -7.58042, "financialCurrency": "USD", "symbol": "PTGX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "regularMarketChangePercent": -0.230843, "regularMarketPrice": 64.83, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1759522204, "regularMarketTime": 1759521600, "exchange": "NGM", "messageBoardId": "finmb_129263324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekChangePercent": 48.0137, "earningsTimestamp": 1754510400, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.73, "epsForward": -1.43, "epsCurrentYear": -1.97772, "priceEpsCurrentYear": -32.78017, "fiftyDayAverageChange": 6.3383026, "fiftyDayAverageChangePercent": 0.10836243, "twoHundredDayAverageChange": 16.035229, "twoHundredDayAverageChangePercent": 0.32862595, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470922200000, "postMarketChangePercent": 0.0, "postMarketPrice": 64.83, "postMarketChange": 0.0, "regularMarketChange": -0.150002, "regularMarketDayRange": "64.56 - 65.38", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 839170, "fiftyTwoWeekLowChange": 31.52, "fiftyTwoWeekLowChangePercent": 0.94626236, "fiftyTwoWeekRange": "33.31 - 68.26", "fiftyTwoWeekHighChange": -3.4300003, "fiftyTwoWeekHighChangePercent": -0.05024905, "displayName": "Protagonist Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]